Positive Interim Phase I Results of Zolmitriptan Transdermal Microporation System for the Treatment of Acute Migraine
SAN DIEGO, March 29, 2024. PassPort Technologies, Inc. (PPTI), based in San Diego, a clinical-stage drug and medical device development company, today announced positive interim results from the Phase 1 (Part A) clinical trial of Zolmitriptan PassPort utilizing its proprietary transdermal microporation system for the treatment of acute migraine. Zolmitriptan is an FDA-approved prescription medication used for treating migraine symptoms.
Zolmitriptan PassPort, a needle-free combination system consisting of a microporation device and zolmitriptan patch, was applied on the individual's upper arm to deliver zolmitriptan into the systemic circulation via micropores painlessly created in the skin.
The open-label, randomized, crossover study consisting of 32 healthy volunteers tested the tolerability and pharmacokinetics of Zolmitriptan PassPort with 3 different doses (0.75 mg, 1.5 mg, and 3.0 mg) compared to oral administration of 2.5 mg zolmitriptan.
Zolmitriptan PassPort was well-tolerated with no serious adverse events. Zolmitriptan was detected in the plasma only 2 minutes after Zolmitriptan PassPort administration, much faster than 15 minutes seen for oral administration. The relative bioavailability of Zolmitriptan PassPort was approximately 160 to 200% compared to oral zolmitriptan.
"We are pleased with the tolerability and pharmacokinetics of Zolmitriptan PassPort in Phase 1 Part A study. Our Zolmitriptan PassPort is expected to demonstrate significant advantages of faster onset of action and higher pain relief for migraine patients with severe nausea and patients who are non-responsive to oral triptans. It will provide a Best-in-Class product option." said President and CEO Tomoyuki Fujisawa.
Part B study, currently underway, will evaluate the transdermal administration of a single dose at alternative sites, the subject's abdomen and upper thigh. The final results will be available to the public in Q3 2024.
PPTI holds exclusive global rights to develop and commercialize the Zolmitriptan PassPort but intends to out-license for further clinical development and commercialization.
About PassPort Technologies, Inc.
As a cutting-edge biotechnology entity, PPTI is committed to the swift development and patient delivery of innovative pharmaceuticals through the PassPort system. The company aims to constantly develop technologies that serve the pharmaceutical industry and broader life sciences sectors. PPTI's mission is to advance global health outcomes.
The PassPort System integrates patented painless skin microporation and dry patch formulation technologies to regulate drug delivery through the micropores created in the skin. This innovative system enables transdermal delivery of not only small molecules but also peptides, proteins, and RNAs for therapeutics and infection vaccines.
Forward-Looking Statement
Except for historical information, all the statements, expectations, and assumptions contained in this Press Release are forward-looking statements. Actual results may differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the early phase of the clinical trial; risks associated with the drug development process; competition; reliance on key personnel; and other risks described in other PassPort Technologies, Inc. press releases and presentations.
SOURCE PassPort Technologies, Inc.
Posted: March 2024
Related articles
- FDA Approves Intermezzo for Middle-of-the-Night Waking Followed by Difficulty Returning to Sleep - November 23, 2011
- Transcept Pharmaceuticals Announces Intermezzo PDUFA Action Date of November 27, 2011 - October 7, 2011
- Transcept Pharmaceuticals Announces Plan to Resubmit Intermezzo New Drug Application Following Meeting with the U.S. Food & Drug Administration - September 14, 2011
- Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo New Drug Application - July 15, 2011
- Transcept Pharmaceuticals Expects Complete Response Letter on Intermezzo New Drug Application Based on Teleconference with FDA - July 13, 2011
- Transcept Pharmaceuticals Resubmits Intermezzo New Drug Application for the Treatment of Middle of the Night Awakenings - January 19, 2011
- Transcept Pharmaceuticals Updates Plan for Intermezzo NDA Resubmission Following Teleconference With the FDA - March 25, 2010
- Transcept Pharmaceuticals Provides Update on Intermezzo Regulatory Review - February 23, 2010
- Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo Complete Response Letter - November 24, 2009
- Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo New Drug Application - October 30, 2009
- Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo - June 11, 2009
- Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo - December 16, 2008
- Transcept Pharmaceuticals Submits New Drug Application for Intermezzo for Treatment of Middle-of-the-Night Awakenings - October 1, 2008
Intermezzo (zolpidem tartrate) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.